tricosan-2-one | 7320-54-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: tricosan-2-one
• 英文别名: 2-Tricosanone
• CAS: 7320-54-9
• 化学式: C₂₃H₄₆O
• 分子量: 338.618
• InChiKey: HMGAHRPPRPQDAS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10.6
• 重原子数：
  24
• 可旋转键数：
  20
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  tricosan-2-one 在 lithium aluminium tetrahydride 作用下， 生成 tricosan-2-ol
  参考文献：
  名称：

  Ubik,K. et al., Collection of Czechoslovak Chemical Communications, 1975, vol. 40, p. 1718 - 1730

  摘要：

  DOI：
• 作为产物：
  描述：

  碘甲烷 在 锌铜偶 、 乙酸乙酯 、 甲苯 作用下， 生成 tricosan-2-one
  参考文献：
  名称：

  Hospital-acquired infections among chronic hemodialysis patients

  摘要：

  The epidemiological characteristics of nosocomial infections among patients requiring chronic hemodialysis, a high-risk and rapidly growing population, have not been fully elucidated. During a 30 month cohort study, rates of bloodstream infections (BSIs), urinary tract infections (UTIs), pneumonia, and diarrhea caused by Clostridium difficile and the distribution of pathogens among hospitalized chronic hemodialysis patients were compared with hospitalized patients not requiring chronic hemodialysis, To identify risk factors for developing a nosocomial infection among chronic hemodialysis patients, a matched case-control study was performed. A total of 1,557 nosocomial infections were detected during 1,317 of 68,361 admissions (2%). Of these, 47 nosocomial infections occurred in chronic hemodialysis patients during 31 of 578 admissions (5%). Nosocomial infections were significantly more frequent among the chronic hemodialysis group (9.1/1,000 patient-days) compared with the non-chronic hemodialysis group (3.8/1,000 patient-days; relative risk [RR], 2.4; 95% confidence interval [CI], 1.8 to 3.2; P < 0.001). UTIs were the most common nosocomial infections among chronic hemodialysis patients, accounting for 47% of all infections in this population. UTIs were significantly more common among chronic hemodialysis patients (4.2/1,000 patient-days) compared with non-chronic hemodialysis patients (0.7/1,000 patient-days; RR, 6.2; 95% CI, 3.8 to 9.5; P < 0.001). Among chronic hemodialysis patients, Candida spp and enterococci were the most common pathogens in contrast to coagulase-negative staphylococci and Staphylococcus aureus among patients not requiring hemodialysis. Using conditional logistic regression, a greater index of comorbidity was significantly associated with nosocomial infections among the chronic hemodialysis population (odds ratio, 3.6; 95% CI, 1.2 to 10.7; P = 0.02), Chronic hemodialysis patients are at a substantially greater risk for developing a nosocomial infection compared with other hospitalized patients. (C) 2000 by the National Kidney Foundation, Inc.

  DOI：

  10.1016/s0272-6386(00)70044-8

文献信息

• Glycerin derivatives and process for producing the same
  申请人：KAO CORPORATION

  公开号：EP0624563A1

  公开（公告）日：1994-11-17

  Glycerine derivatives represented by formula (1A), (2A) and (3A): wherein R1a, R2a, R1b, R2b, R1c, and R2c are as defined in the disclosure, and process for producing glycerin derivatives, including the glycerin derivatives (1A), (2A) and (3A), are disclosed. The glycerin derivatives have satisfactory physical properties and are applicable as lubricants or polar oils and also have mutual effects with water and are applicable as emulsifying agents or moisture retaining agents. The process makes it possible to synthesize glycerin derivatives from easily and economically available aldehydes or ketones in high yields.

  公式（1A）、（2A）和（3A）代表的甘油衍生物：其中R1a、R2a、R1b、R2b、R1c和R2c如披露中所定义，并公开了生产甘油衍生物的方法，包括甘油衍生物（1A）、（2A）和（3A）。这些甘油衍生物具有令人满意的物理性质，可用作润滑剂或极性油，并且与水有相互作用，可用作乳化剂或保湿剂。该方法使得可以从易于获得且经济可行的醛类或酮类高产率地合成甘油衍生物。
• METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND FOR THE TREATMENT OF ADRENOLEUKODYSTROPHY
  申请人：Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)

  公开号：EP3118621A1

  公开（公告）日：2017-01-18

  The present invention is directed to a diagnostic method for adrenoleukodystrophy in a subject based on the determination of the levels of different markers. The invention also provides a method for monitoring the progression of an adrenoleukodystrophy, a method for monitoring the effect of an adrenoleukodystrophy therapy and fingolimod, an analogue, metabolite or derivative thereof, or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of an adrenoleukodystrophy.

  本发明涉及一种基于不同标记物水平测定的受试者肾上腺脑白质营养不良症的诊断方法。本发明还提供了一种监测肾上腺白质营养不良症进展的方法、一种监测肾上腺白质营养不良症治疗效果的方法以及用于治疗和/或预防肾上腺白质营养不良症的芬戈莫德、其类似物、代谢物或衍生物或其药学上可接受的盐。
• THICKENING STABILIZER AND SOLVENT COMPOSITION USING SAME FOR PRODUCTION OF ELECTRONIC DEVICE
  申请人：Daicel Corporation

  公开号：EP3778564A1

  公开（公告）日：2021-02-17

  Provided is a compound that thickens a fluid organic material to a desired viscosity and uniformly stabilizes composition thereof. A compound of the present invention is represented by Formula (1): where R1 represents a monovalent linear aliphatic hydrocarbon group having from 10 to 25 carbons; R2 and R3 are the same or different, representing a divalent aliphatic hydrocarbon group having 2, 4, 6, or 8 carbons, a divalent alicyclic hydrocarbon group having 6 carbons, or a divalent aromatic hydrocarbon group; R4 represents a divalent aliphatic hydrocarbon group having from 1 to 8 carbon(s); R5 and R6 are the same or different, representing a monovalent aliphatic hydrocarbon group having from 1 to 3 carbon(s) or a hydroxyalkylether group; L1 to L3 represent an amide bond; in a case where L1 and L3 are -CONH-, L2 is -NHCO-, and in a case where L1 and L3 are -NHCO-, L2 is -CONH-.

  本发明提供了一种化合物，可将流体有机材料增稠至所需的粘度，并均匀地稳定其成分。本发明的化合物由式（1）表示：其中 R1 代表具有 10 至 25 个碳原子的一价线性脂族烃基；R2 和 R3 相同或不同，代表具有 2、4、6 或 8 个碳原子的二价脂族烃基、具有 6 个碳原子的二价脂环烃基或二价芳香烃基；R4 代表具有 1 至 8 个碳的二价脂族烃基； R5 和 R6 相同或不同，代表具有 1 至 3 个碳的一价脂族烃基或羟基烷基醚基； L1 至 L3 代表酰胺键；在 L1 和 L3 为-CONH-的情况下，L2 为-NHCO-，在 L1 和 L3 为-NHCO-的情况下，L2 为-CONH-。
• 天然資源から抽出した生物活性物質の医薬製剤
  申请人：——

  公开号：JP2003500452A

  公开（公告）日：2003-01-07

  \n (57)【要約】\n本発明は、種々の草木及び草本から生物活性物質を抽出し、精製する方法に関する。さらに具体的には、発明は、超臨界流体抽出及び／又はフルオロカーボン溶媒抽出を用いて、カバの根、ビルソニマ種、アスクルス・カリフォルニカ、クラタガス・メキシカーナ、シモンドシア・キネンシス、ファフィア種、アルテルナンテラ・レペンス、ブルセラ種、ツルネラ種、ペレジア種、ヘイミア・サリシフォリア、シジウム種、エンテロロビウム種、チコペタラム・オラコイデス、リリオスマ・オバタ及びチャウノチトン・カッペレリのような草木及び草本から生物活性物質を抽出し、分離する方法に関する。本発明はさらに、移動相において気体が調整剤を伴う又は伴わない充填カラム超臨界流体クロマトグラフィ又はＨＰＬＣを用いた、抽出物中に含有される生物活性物質の分離に関する。本発明はまた、抽出される生物活性物質から調製されてもよい医薬製剤並びに栄養補助食品、及びヒトの種々の病気を治療するためのかかる医薬製剤並びに栄養補助食品の使用に関する。\n

  \(57)/n (57)/n (57)/n (57)/n (57)/n (57)/n (57)/n (57)/n (57)} 本发明涉及从各种草药和植物中提取和纯化生物活性物质的方法。更具体地说，本发明使用超临界流体萃取和/或碳氟化合物溶剂萃取来提取和纯化河马根、Bilsonima species、Aesculus californica、Clatagus mexicana、Simmondsia quinensis、Phaffia species、Alternanthera repens、Brucella species、Tunella species 中的生物活性物质、本发明涉及一种从禾本科植物和草本植物（如 Peresia species、Haymia salicifolia、 Sidium species、Enterolobium species、Chicopetalum oracoides、Liliosma ovata 和 Chaunochiton caperelli）中提取和分离生物活性物质的方法。本发明还涉及使用填料柱超临界流体色谱法或高效液相色谱法分离提取物中含有的生物活性物质，在流动相中使用或不使用气体调节剂。本发明还涉及可从待提取的生物活性物质中制备的药物制剂和膳食补充剂，以及使用这些药物制剂和膳食补充剂治疗各种人类疾病。\n
• Opioid receptor antagonist prodrugs
  申请人：Nirsum Laboratories, Inc.

  公开号：US10544154B2

  公开（公告）日：2020-01-28

  Provided herein are prodrugs of opioid receptor antagonists such as nalmefene and naltrexone, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of behavioral disorders.

  本文提供了阿片受体拮抗剂（如纳美芬和纳曲酮）的原药、包含所述化合物的药物组合物以及使用所述化合物治疗行为紊乱的方法。